TY - JOUR
T1 - Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients
AU - Chin, Kazuo
AU - Nakamura, Takaya
AU - Takahashi, Kenichi
AU - Sumi, Kensuke
AU - Ogawa, Yoshihiro
AU - Masuzaki, Hiroaki
AU - Muro, Shigeo
AU - Hattori, Noboru
AU - Matsumoto, Hisako
AU - Niimi, Akio
AU - Chiba, Tsutomu
AU - Nakao, Kazuwa
AU - Mishima, Michiaki
AU - Ohi, Motoharu
AU - Nakamura, Takashi
N1 - Funding Information:
This work was supported in part by grants from the Tahei Ueda Memorial Fund; the Japan Vascular Disease Research Foundation; the Japanese Ministry of Education, Culture, Sports, Science, and Technology; and the Japanese Ministry of Health, Labour and Welfare.
PY - 2003/4/1
Y1 - 2003/4/1
N2 - PURPOSE: Obesity has been associated with obstructive sleep apnea and hepatic steatosis. We investigated the effects of obstructive sleep apnea and treatment with nasal continuous positive airway pressure (CPAP) on serum aminotransferase levels in obese patients. METHODS: We studied 40 obese men with obstructive sleep apnea syndrome. None had hepatitis B antigen or C antibody, autoimmune disease, or an excessive intake of alcohol. Serum levels of aspartate aminotransferase, alanine aminotransferase, triglyceride, glucose, insulin, and leptin were determined in the afternoon and in the morning immediately after sleep, before and after nasal CPAP treatment. RESULTS: Aminotransferase levels were abnormal in 35% (n = 14) of patients. Before treatment, mean (± SD) aspartate aminotransferase levels were higher in the morning than in the previous afternoon (presleep, 34 ± 20 IU/L; postsleep, 39 ± 28 IU/L; P = 0.006). The overnight mean increases in aminotransferase levels were less marked after the first night of nasal CPAP treatment (aspartate aminotransferase: from 6 ± 11 IU/L to 2 ± 6 IU/L, P = 0.0003; alanine aminotransferase: from 5 ± 9 IU/L to 2 ± 6 IU/L, P = 0.006). Leptin levels (n = 23) decreased significantly after treatment (P = 0.0002), whereas insulin resistance (calculated by the homeostasis model assessment method) and triglyceride levels were unchanged. Improvements in aspartate and alanine aminotransferase levels were maintained after 1 and 6 months of nasal CPAP treatment. CONCLUSION: Nasal CPAP therapy may have beneficial effects on serum aminotransferase abnormalities in obese patients who have obstructive sleep apnea.
AB - PURPOSE: Obesity has been associated with obstructive sleep apnea and hepatic steatosis. We investigated the effects of obstructive sleep apnea and treatment with nasal continuous positive airway pressure (CPAP) on serum aminotransferase levels in obese patients. METHODS: We studied 40 obese men with obstructive sleep apnea syndrome. None had hepatitis B antigen or C antibody, autoimmune disease, or an excessive intake of alcohol. Serum levels of aspartate aminotransferase, alanine aminotransferase, triglyceride, glucose, insulin, and leptin were determined in the afternoon and in the morning immediately after sleep, before and after nasal CPAP treatment. RESULTS: Aminotransferase levels were abnormal in 35% (n = 14) of patients. Before treatment, mean (± SD) aspartate aminotransferase levels were higher in the morning than in the previous afternoon (presleep, 34 ± 20 IU/L; postsleep, 39 ± 28 IU/L; P = 0.006). The overnight mean increases in aminotransferase levels were less marked after the first night of nasal CPAP treatment (aspartate aminotransferase: from 6 ± 11 IU/L to 2 ± 6 IU/L, P = 0.0003; alanine aminotransferase: from 5 ± 9 IU/L to 2 ± 6 IU/L, P = 0.006). Leptin levels (n = 23) decreased significantly after treatment (P = 0.0002), whereas insulin resistance (calculated by the homeostasis model assessment method) and triglyceride levels were unchanged. Improvements in aspartate and alanine aminotransferase levels were maintained after 1 and 6 months of nasal CPAP treatment. CONCLUSION: Nasal CPAP therapy may have beneficial effects on serum aminotransferase abnormalities in obese patients who have obstructive sleep apnea.
UR - http://www.scopus.com/inward/record.url?scp=0037396722&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037396722&partnerID=8YFLogxK
U2 - 10.1016/S0002-9343(02)01570-X
DO - 10.1016/S0002-9343(02)01570-X
M3 - Article
C2 - 12714126
AN - SCOPUS:0037396722
SN - 0002-9343
VL - 114
SP - 370
EP - 376
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 5
ER -
